[Skip to Content]
[Skip to Content Landing]
February 1992

Antithrombin III Level, Fibrinogen Level, and Platelet Count Changes With Adjuvant Tamoxifen Therapy

Author Affiliations

From the Cancer Prevention Program, University of Wisconsin Clinical Cancer Center, and the Departments of Human Oncology and Medicine, University of Wisconsin, Madison.

Arch Intern Med. 1992;152(2):317-320. doi:10.1001/archinte.1992.00400140065015

Adjuvant therapy for breast cancer with tamoxifen is suggested to be of benefit to both women with negative and women with positive axillary nodes, and treatment lasting several years is currently being investigated. Venous thrombophlebitis may complicate tamoxifen treatment at a rate of approximately one per 800 treatment-years. To explore the possible mechanisms of this effect, we evaluated changes in antithrombin III levels, fibrinogen levels, and platelet counts in 140 postmenopausal women with surgically resected breast cancer who were disease free and participating in a double-blind, placebo-controlled, randomized toxicity study of tamoxifen. Antithrombin III levels, elevated at baseline evaluation, decreased in tamoxifentreated subjects at 6 months, but no subject exhibited a drop to clinically significant levels. Fibrinogen levels decreased 15% (0.4 g/L) in tamoxifen-treated subjects at 6 months. Platelet counts decreased 7% to 9% from baseline to evaluations at 3, 6,12,18, and 24 months in tamoxifen-treated subjects. While these changes do not explain the possible small thrombophlebitis-promoting effect of tamoxifen, the decrease in fibrinogen levels might be expected to be associated with a decreased risk of arterial thrombosis.

(Arch Intern Med. 1992;152:317-320)